Trend Results : American Society of Hematology


Blog Post Results (1-20 of 130)

FILTER RESULTS

Late-breaking hematology abstracts signal new, near-term therapeutic options for patients

(American Society of Hematology) In four clinical trials being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers report promising results suggesting patients with blood disorders and several types of cancer will soon have significantly expanded options for treatment. Show More Summary

Dana-Farber/Brigham and Women's physician wins prestigious recognition from ASH

(Dana-Farber Cancer Institute) Benjamin Ebert, M.D., Ph.D., current chair of Medical Oncology, was presented with recognition at annual American Society of Hematology meeting. Ebert is notable for his leadership in describing the genomic landscape of adult myelodysplastic syndromes (MDS).

Transfusion dependence a barrier to quality end-of-life care for some with leukemia

(American Society of Hematology) For patients with advanced leukemia, access to high-quality end-of-life care appears to be reduced in those dependent on blood transfusions, according to a new study being presented during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta. Show More Summary

People aged 75 years and older are underrepresented in blood cancer clinical trials

(American Society of Hematology) In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the US FDA found significant gaps in participation among those aged 75 and older...Show More Summary

Survivorship care plan improves cancer care-related distress levels for HCT recipients

(Be The Match) Survivorship care plan improves patient cancer care-related distress levels for hematopoietic cell transplant recipients. Results from a recent multicenter study presented at the American Society of Hematology (ASH) Annual Meeting.

CAR T-cell therapies drive outcomes in lymphoma, myeloma

(American Society of Hematology) For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American Society of Hematology (ASH)Show More Summary

Five Winners – And One Loser – From Medicine’s Big Meeting About Blood

For the past two days, doctors who treat blood diseases have been meeting at the annual convention of the American Society of Hematology in Atlanta. There’s a lot of innovation coursing through this field. Here’s a guide to companies who are standing out.

Bioengineering and specialized therapies yield results for rare, challenging blood diseases

(American Society of Hematology) In four studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers announce promising findings on innovative tools and therapies...Show More Summary

New therapies improve outlook for bleeding and clotting disorders

(American Society of Hematology) In three studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers report remarkable benefits from new, more easily administered therapies for bleeding and clotting disorders, including hemophilia A and people with cancer experiencing venous thromboembolism.

Targeted therapies show promise improving outcomes across several hematologic malignancies

(American Society of Hematology) Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality of life for patients with rare, advanced, or difficult-to-treat blood malignancies.

Spark Shadows BioMarin In Hemophilia Gene Therapy Race

Spark Therapeutics, the company likely to launch the first gene therapy in the U.S., is presenting data on both of its gene therapies for hemophilia this morning at the annual meeting of the American Society of Hematology in Atlanta...

Physical activity data, emojis on Apple Watch correlated with patient-reported outcomes

ATLANTA - In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients' physical, emotional and overall quality of life. Show More Summary

Immunotherapy drug nearly eliminates severe acute graft-versus-host disease

(Seattle Children's) Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.

Immunotherapy Strategy Could Be Beneficial for Relapsed Acute Myeloid Leukemia, Preliminary Data Show

Researchers present their preliminary results from the ongoing phase II trial of chemotherapy and pembrolizumab in relapsed or refractory acute myeloid leukemia at the 59th American Society of Hematology Annual Meeting in Atlanta on Saturday, Dec. 9.

Mayo Clinic Study Finds Emojis Promising Tool for Tracking Cancer Patients' Quality of Life

In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients' physical, emotional and overall quality of life....Show More Summary

Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant

Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.

Dr. Mohamad Cherry of Atlantic Hematology Oncology to Lead Meeting Session and Help Present Multiple Studies at Top International Blood Cancer Meeting

Mohamad Cherry, MD, will lead a major session on new discoveries about the most common type of acute adult leukemia and help present results of four major blood cancer studies at the American Society of Hematology (ASH) 59th Annual Meeting, December 9-12 in Atlanta, GA. Show More Summary

John Theurer Cancer Center Researchers Share 46 Cutting Edge Studies at 2017 ASH Meeting

Researchers from the Hackensack Merdian Health John Theurer Cancer Center at Hackensack University Medical Center will present results from 46 cancer-related studies during the American Society of Hematology (ASH) 59th Annual Meeting, which will take place December 9 - 12, 2017 in Atlanta. Show More Summary

MD Anderson to present key drug study findings for multiple blood cancers at ASH annual meeting

(University of Texas M. D. Anderson Cancer Center) Researchers at The University of Texas MD Anderson Cancer Center will present their latest findings involving drug treatments for blood cancers at the American Society of Hematology's (ASH) Annual Meeting & Exposition Dec. 8-12 in Atlanta.

MD Anderson to Present Key Drug Study Findings for Multiple Blood Cancers at ASH Annual Meeting

Researchers at The University of Texas MD Anderson Cancer Center will present their latest findings involving drug treatments for blood cancers at the American Society of Hematology's (ASH) Annual Meeting & Exposition Dec. 8-12 in Atlanta.

Copyright © 2015 Regator, LLC